Gilead Sciences Acquires Ouro Medicines for $1.675 Billion to Expand Autoimmune Therapy Portfolio

Gilead Sciences to acquire Ouro Medicines for $1.675 bln upfront, plus $500 mln in contingent milestone payments. The acquisition adds OM336, a clinical-stage BCMAxCD3 bispecific T cell engager, to Gilead's inflammation portfolio, with potential registrational studies starting in 2027. Gilead is in discussions with Galapagos for a potential R&D collaboration on the Ouro portfolio.